FOLLOW US

In a nail-biting legal tussle, Eli Lilly & Co. has managed to successfully overturn a $176.5 million verdict previously won by Teva Pharmaceuticals for a migraine drug patent infringement. The legal duel saw Massachusetts federal judge, Allison D. Burroughs, declaring the three patents associated with Teva’s Ajovy as void.

 A Pivot in Judicial Assessment:

In a meticulous judgment, Judge Burroughs supported Eli Lilly’s motion, ruling out the prior jury's verdict and stated the undeniable evidence reveals the non-existence of a representative count of humanized antibodies in Teva’s patents. These antibodies bind with the migraine-triggering calcitonin gene-related peptide (CGRP). “The disclosure of a single species is not enough to support the extensive range of these asserted claims,” iterated Judge Burroughs.

Eli Lilly $177M Migraine Drug : The Lawsuit Chronicle:

The legal fire was ignited in 2018 when Teva threw the first legal punch just after Eli Lilly’s Emgality received the FDA’s green light. Eli Lilly counteracted by dragging Teva to the Patent Trial and Appeal Board, questioning the validity of nine Ajovy-related patents.

Teva accused Eli Lilly of engaging in a $1 billion marketing expedition to establish Emgality as the superior migraine solution, overshadowing Teva’s innovation. Eli Lilly found themselves indebted to pay $176.5 million to Teva after the jury found them guilty of infringing Teva’s three patents willingly. The jury dismissed Eli Lilly’s defense regarding the invalidity of Teva’s patents.

The Verdict Overturn and its Aftermath:

In a twist of fate, Judge Burroughs ruled in favor of Eli Lilly, concluding that Teva's patents were inadequate in describing a representative variety of antibodies. Eli Lilly dodged the bullet by proving the incapability of Teva’s patents to describe the invention sufficiently, marking them invalid due to lack of enablement and written description.

Yet, the judge denied Eli Lilly’s appeal on the future lost profits, a whopping $49.8 million, awarded to Teva by the jury. The jury’s decision on future lost profits remained unscathed as it was based on actual sales data and plausible projections, despite being substantially lesser than the expert’s calculation.

Unsettling Tides at the Patent Board:

To add to the intrigue, Eli Lilly secured notable victories at the Patent Trial and Appeal Board, challenging more recent patents held by Teva for Ajovy, unrelated to last year's court fracas in Boston. The court sided with Eli Lilly, finding that elements of the newer patents were already present in previous applications, combined with insights from a 2014 Lancet Neurology paper by researcher David Dodick from Mayo Clinic. A ruling on Eli Lilly’s challenge to a third new Teva patent is still awaited.

Eli Lilly $177M Migraine Drug : Epilogue

The tension remains palpable, and the combatants have retreated, yet the legal war seems far from over. The silence before the next legal storm is filled with anticipations and speculations, while the legal representatives prepare for the next chapter in this intellectual property saga.

 Representations

Teva was represented by Goodwin Procter LLP, and Eli Lilly by Burns & Levinson LLP and Finnegan Henderson Farabow Garrett & Dunner LLP, with various associates and representatives engaged at the patent board.

This fascinating legal bout between giants serves as a dramatic reminder of the high-stakes battles in the pharmaceutical industry, where intellectual property becomes a fiercely contested battleground, and millions hang in the delicate balance of legal scales. The overturned verdict has not only shifted the limelight back to Eli Lilly but has also opened new avenues of legal discussions and evaluations in the world of pharmaceutical patents.